FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

SECURITIES AND	EXCHANGE	COMMIN
Washington D.C.	20540	

OMB APP	ROVAL
OMP Number:	3335 030

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to exist the office of the indicate of the restrict of the office of the section. to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lanfear Dennis M</u>				2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS]							(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				ner	
(Last) (First) (Middle) C/O COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600					3. Date of Earliest Transaction (Month/Day/Year) 01/10/2025							Officer (give title Other (specify below) President & CEO					
(Street) REDWC CITY (City)	C.	A tate)	94065 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Form fi				
(Oity)			ble I - Nor	n-Deriva	tive S	ecurities	s Ac	quired,	Dist	osed c	of, or Be	eneficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date			2. Transac Date (Month/Da	Execution Date,		Code (Instr.				5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) (D)	or Price	Transacti	Transaction(s) (Instr. 3 and 4)			msu. 4)	
			Table II -	Derivati (e.g., pu									Owned				
Derivative Conversion Da		3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3A. Deemed Execution I if any (Month/Day		Oate, Transaction Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cod	le V	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Stock Option	\$1.47	01/10/2025		A		575,000		(1)	0	1/10/2035	Common	575,000	\$0	575,0	00	D	

Explanation of Responses:

(Right to

1. The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 10, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. 01/14/2025 Lanfear

** Signature of Reporting Person Date

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.